TriangleSitagliptin (NCT07541781)
Sitagliptin trial for Glioma (NCT07541781). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for grade 4 glioma, a brain tumor, that has returned or progressed after first line therapy, in adults.
The idea: use sitagliptin to inhibit myeloid derived suppressor cells, together with the standard of care drug bevacizumab. Doses are adjusted to find the maximal tolerated dose. The goal is proof of concept that suppressing these cells is safe and feasible.
This phase 1 trial plans 45 patients. At the University of Iowa in Iowa City, Kailin Yang leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.